About the Company
Sarfez Pharmaceuticals, Inc. is a Virginia company focused on improving existing drugs using proprietary extended release formulation technology, repurposing older drugs for new uses and designing new molecules to target specific patient needs to treat cardiovascular and kidney diseases.
Sarfez is developing innovative treatments for lifestyle related diseases with a team who has been involved with the scientific and drug development community for decades. Our team includes academic leaders, internationally renowned physicians and scientists specializing in nephrology and hypertension, and entrepreneur Salim Shah, Ph.D., J.D., a 20-year veteran within the scientific and biotechnology development community with extensive pharmaceutical experience in the United States, Japan, China and India.
Our team brings wide-ranging experiences from academic, industry, and public sector areas.
Sarfez has a world class Scientific Advisory Committee - Christopher Wilcox, M.D., Ph.D. (physician scientist); Bertram Pitt, M.D., (clinical investigator) Domenic Sica, M.D., PhD, (clinical scientist); Peter Feig, M.D. (former pharma executive); and Guru Betgeri, Ph.D. (pharmaceutical scientist); and an experienced Management Team - Fatima Khwaja (CEO); and Peter Feig (CMO).